Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation01-04-2018
Cadila Healthcare stock: Analysts see 20% compounded growth in US sales
While analysts have cut their forward net profit estimates to factor in the challenges, the correction in stock prices, according to them, is exaggeratedAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
Cadila Healthcare's Topical facility successfully completes USFDA inspectionDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ramanbhai B Patel HUFDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pankaj Ramanbhai Patel HUFDisclosure Under Regulation 29(2) Of The SEBI SAST Regulations, 2011
Disclosure under regulation 29(2) of the SEBI SAST Regulations, 2011Zydus Cadila gets USFDA nod for cardiac drug
Zydus Cadila has received final approval from USFDA to market Metoprolol Succinate extended-release tablets USPVolume Shockers today: Cadila Healthcare, Unichem, Gulf Oil Lubricants, Chambal Fertilizers
Cadila Healthcare is one of the stocks dominating the volume shockers screener today, gaining after the company said Zydus Cadila has received final approval from the US regulator for Metoprolol Succinate extended-release tablets. The drug is used to treat chest pain, heart failure and high blood pressure. Other volume shockers today include Unichem Labs, as well as Chambal Fertilizers.Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Metoprolol Succinate Extended-Release Tablets USPAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Omeprazole and Sodium Bicarbonate Capsules.